Form 4: Contineum Therapeutics Insider Sells Shares
Statement of Changes in Beneficial Ownership
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A Common Stock for $13.43 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc., reported a transaction on April 6, 2026.
- He sold 4,170 shares of Class A Common Stock.
- The sale was executed at a weighted average price of $13.43 per share, with individual transactions ranging from $13.08 to $13.60.
- These shares were sold as part of a 10b5-1 trading plan adopted on September 23, 2025.
- Following the transaction, Lorrain directly beneficially owns 147,712 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the transaction was conducted under a pre-arranged 10b5-1 plan, mitigating concerns about opportunistic trading.
Negatives
- Insider selling can sometimes be interpreted as a lack of confidence in the company's future prospects, although this sale was conducted under a pre-established trading plan.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it solely reports a change in beneficial ownership.
Industry Context
StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to allow executives to trade company stock without violating insider trading laws. The execution of such a plan indicates a pre-determined strategy for stock disposition.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| 10b5-1 Trading Plan | Transaction executed pursuant to a written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 09/23/2025 | Ensures compliance with insider trading regulations by establishing a pre-determined trading strategy. |
Stakeholder Impact
- Shareholders: The sale of shares by a key executive may lead to short-term market scrutiny, though the 10b5-1 plan structure aims to depersonalize the transaction.
Key Dates
| Date | Description |
|---|---|
| 09/23/2025 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 04/06/2026 | Date of the reported transaction (sale of shares). |
Keywords
Contineum Therapeutics, CTNM, Form 4, Insider Trading, 10b5-1 plan, Stock Sale, Class A Common Stock, Securities and Exchange Commission
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.